Literature DB >> 602233

Personal experience with Corynebacterium parvum in human cancers.

L Israël, R Edelstein.   

Abstract

Entities:  

Mesh：

Year:  1977        PMID： 602233     DOI： 10.1007/bf01556183

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  15 in total

1.  Combined chemoimmunostimulation therapy against murine leukemia.

Authors:  J W Pearson; G R Pearson; W T Gibson; J C Chermann; M A Chirigos
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

2.  Non-specific immunostimulation in bronchogenic cancer.

Authors:  L Israel
Journal:  Scand J Respir Dis Suppl       Date:  1974

3.  [Corynebacterium parvum in advanced cancers. 1st evaluation of the therapeutic activity of this immunostimulin].

Authors:  L Israël; B Halpern
Journal:  Nouv Presse Med       Date:  1972-01-01

4.  Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia.

Authors:  E M Hersh; J P Whitecar; K B McCredie; G P Bodey; E J Freireich
Journal:  N Engl J Med       Date:  1971-11       Impact factor: 91.245

5.  Plasmapheresis and immunological control of cancer.

Authors:  L Israel; R Edelstein; P Mannoni; E Radot
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

6.  Hydrosoluble immunopotentiating substances extraced from Corynebacterium parvum.

Authors:  D Migliore-Samour; M Korontzis; P Jollès
Journal:  Immunol Commun       Date:  1974

7.  Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.

Authors:  L Israël; R Edelstein; A Depierre; N Dimitrov
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

8.  [Letter: Immune and tumor reactions to plasma exchange in advanced cancers].

Authors:  L Israel; P Mannoni; E Radot; E Greenspan
Journal:  Nouv Presse Med       Date:  1976-02-14

9.  Complement activation in vivo in cancer patients receiving C. parvum immunotherapy.

Authors:  H Biran; J L Moake; R C Reed; J U Gutterman; E M Hersh; E J Freireich; G M Mavligit
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

10.  Serum lysozyme as a marker of host resistance. I. Production by macrophages resident in rat sarcomata.

Authors:  G A Currie; S A Eccles
Journal:  Br J Cancer       Date:  1976-01       Impact factor: 7.640
View more
  5 in total

1.  Hypercoagulability after immunotherapy with Corynebacterium parvum in man.

Authors:  J Harenberg; A Baumgärtner; D Fritze; R Zimmermann
Journal:  Blut       Date:  1982-04

2.  Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: a randomized study comparing different times and routes of administration of Corynebacterium parvum.

Authors:  D Fritze; B Massner; R Becher; M Kaufmann; H J Illiger; J Hartlapp; W Queisser; U Abel; L Edler; A C Mayr
Journal:  Klin Wochenschr       Date:  1984-02-15

3.  A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer.

Authors:  D Fritze; R Becher; B Massner; M Kaufmann; U Bruntsch; W M Gallmeier; A C Mayr; P Drings; U Abel; L Edler; W F Jungi; W Queisser; H J Senn
Journal:  Klin Wochenschr       Date:  1982-06-15

4.  Corynebacterium parvum enhances colonic cancer in dimethylhydrazine-treated rats.

Authors:  J P Cruse; M R Lewin; C G Clark
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

5.  Adjuvant therapy in colorectal cancer.

Authors:  A K House
Journal:  J R Soc Med       Date:  1984-06       Impact factor: 18.000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.